BCMA single-domain antibodies and BCMA-CAR-T cells and their preparation and application

By designing single-domain antibodies that specifically target BCMA and chimeric antigen receptor CAR-T cells, the problems of relapse and drug resistance after treatment of multiple myeloma have been solved, and the efficiency and safety of tumor cell killing have been improved.

CN117534762BActive Publication Date: 2026-11-10CARBIOGENE THERAPEUTICS CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202311714287.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-12-14
Publication Date
2026-11-10
Estimated Expiration
2043-12-14

AI Technical Summary

Technical Problem

Existing BCMA-targeted CAR-T cell therapy for multiple myeloma suffers from relapse and drug resistance issues after treatment. Furthermore, CAR-T cells have poor proliferation capacity in vivo, low efficiency in killing tumor cells, and are prone to causing toxic side effects.

Method used

A single-domain antibody and chimeric antigen receptor CAR-T cell specifically targeting BCMA were designed, containing specific amino acid sequences and domains, including the CD8a hinge region, CD8a transmembrane region, and intracellular signaling region, to improve the affinity and killing efficiency of CAR-T cells.

Benefits of technology

It improved the killing efficiency of CAR-T cells against BCMA-positive tumor cells, significantly inhibited tumor cell proliferation, prolonged the survival time of mice, and reduced the occurrence of toxic side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004605603210000011
    Figure HDA0004605603210000011
  • Figure HDA0004605603210000012
    Figure HDA0004605603210000012
  • Figure HDA0004605603210000013
    Figure HDA0004605603210000013
Patent Text Reader

Abstract

This invention discloses a BCMA single-domain antibody and BCMA-CAR-T cells, as well as their preparation and applications. Specifically, it discloses a single-domain antibody that specifically targets BCMA and a chimeric antigen receptor containing this single-domain antibody (SEQ ID No. 1). This invention also discloses CAR-T cells containing the aforementioned chimeric antigen receptor (BCMA-VHH CAR-T cells). Experiments have demonstrated that BCMA-VHH CAR-T cells can effectively secrete the T cell-specific effector molecule IFN-γ, effectively and specifically killing BCMA. + The target cells exhibit excellent in vivo tumor-killing activity, significantly inhibiting tumor cell proliferation in mice and significantly prolonging their survival time. The BCMA-VHH CAR-T cells of this invention demonstrate good anti-tumor activity and can be used for immunotherapy of BCMA-targeted diseases, showing broad clinical application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of cell immunotherapy technology, specifically involving BCMA single-domain antibodies and BCMA-CAR-T cells, as well as their preparation and application. Background Technology

[0002] Multiple myeloma (MM) is a malignant plasma cell disease characterized by abnormal proliferation of plasma cells in the bone marrow, secreting monoclonal immunoglobulins or fragments thereof (M protein). It is a common hematologic malignancy, accounting for 10% of all hematologic malignancies. Common symptoms of MM include myeloma-related organ dysfunction and secondary amyloidosis. Excessive immunoglobulin secretion and uncontrolled plasma cell proliferation cause damage to end organs, ultimately leading to death. Conventional treatments for MM include proteasome inhibitors, immunosuppressants, and anti-CD38 monoclonal antibodies, but these often result in poor clinical outcomes, with low remission and survival rates. The Chinese Guidelines for the Diagnosis and Treatment of Multiple Myeloma (2022 Revision) recommend autologous hematopoietic stem cell transplantation (ASCT) as the first-line treatment for MM patients with good overall performance status. For younger patients with high-risk prognostic factors and suitable donors, allogeneic hematopoietic stem cell transplantation (Allo-SCT) may be considered.

[0003] Currently, CAR-T therapy targeting BCMA has demonstrated clinical efficacy in multiple myeloma. BCMA (B-cell maturation antigen), also known as CD269 or TNFRSF17, is a type III transmembrane glycoprotein belonging to the human tumor necrosis factor receptor (TNFR) superfamily, playing a major role in B cell maturation and differentiation into plasma cells. BAFF and APRIL are two B-cell activation and amplification inducing ligands that bind to BCMA, jointly regulating B-cell function. Studies have shown that BCMA is widely expressed in multiple myeloma cell lines, and consistent results have been obtained in multiple myeloma patients. Building upon existing reports, Carpenter et al. further investigated the expression characteristics of BCMA using a combination of Q-PCR, flow cytometry, and immunohistochemistry, confirming that BCMA is not expressed in normal human tissues other than mature B cells and plasma cells, and is also not expressed in CD34+ hematopoietic cells. Therefore, BCMA has become a popular target for immunotherapy strategies in multiple myeloma and other hematologic malignancies. bb2121 (Abecma) is the first BCMACAR-T cell therapy to receive regulatory approval. In the pivotal Phase II KarMMa study, 73% of patients received a single infusion of Abecma achieved a durable and effective response, and 33% achieved a strict complete response. Furthermore, Abecma has a well-established safety profile in treated patients, with cytokine release syndrome (CRS) and neurotoxicity (NT) mostly being low-grade and rapidly resolving.

[0004] Chimeric antigen receptor (CAR) technology uses genetic engineering to modify immune cells, enabling them to express exogenous anti-tumor genes (CAR genes). This allows immune cells, such as lymphocytes, to recognize tumor cell surface antigens and specifically recognize and kill tumor cells, without the limitations of the histocompatibility complex (MHC). The CAR structure mainly consists of an extracellular domain for recognizing tumor cell surface antigens and an intracellular signal transduction domain. The extracellular domain specifically recognizes tumor-specific proteins (antigens), while the intracellular domain contains a co-stimulatory molecular domain, which initiates an immune response in lymphocytes after recognizing tumor-specific proteins (antigens). This cytotoxic effect targets specific tumor cells, thereby killing them.

[0005] Although CAR-T cell therapy targeting BCMA has shown durable remission rates in multiple myeloma, relapse and drug resistance are frequent after treatment. Furthermore, the poor proliferative capacity of CAR-T cells in vivo and their low efficiency in killing tumor cells objectively increase the dosage required, easily leading to strong toxic side effects such as cytokine storms and central nervous system toxicity. Therefore, there is still an urgent need to modify the design of BCMA-targeting CAR-T cells and find antibodies with good affinity for BCMA to further improve the therapeutic efficacy, safety, and effectiveness of BCMA CAR-T therapy. Summary of the Invention

[0006] One objective of this invention is to provide a single-domain antibody that specifically targets BCMA and CAR-T cells that target BCMA. The technical problems to be solved are not limited to the described technical topics; other technical topics not mentioned herein will be clearly understood by those skilled in the art through the following description.

[0007] To achieve the above objectives, the present invention first provides a single-domain antibody that specifically targets BCMA, wherein the single-domain antibody comprises a complementarity-determining region CDR1 at positions 47-54 of SEQ ID No. 1, a complementarity-determining region CDR2 at positions 72-78 of SEQ ID No. 1, and a complementarity-determining region CDR3 at positions 117-127 of SEQ ID No. 1, respectively.

[0008] Furthermore, the amino acid sequence of the single-domain antibody may be any of the following:

[0009] A1) Bits 22-138 of SEQ ID No. 1;

[0010] The amino acid sequences shown in A2) and A1) have at least 80% identity and the same function.

[0011] The present invention also provides a chimeric antigen receptor (CAR), wherein the chimeric antigen receptor comprises the single-domain antibody.

[0012] The single-domain antibody is the antigen-binding domain of the chimeric antigen receptor.

[0013] Furthermore, the chimeric antigen receptor may also include a CD8a hinge region, a CD8a transmembrane region, and an intracellular signaling region, wherein the intracellular signaling region may include a co-stimulatory domain 4-1BB and an activation domain CD3ζ.

[0014] Furthermore, the amino acid sequence of the CD8a hinge region may be positions 139-183 of SEQ ID No. 1.

[0015] Furthermore, the amino acid sequence of the transmembrane region of CD8a may be positions 184-207 of SEQ ID No. 1.

[0016] Furthermore, the amino acid sequence of 4-1BB may be positions 208-254 of SEQ ID No. 1.

[0017] Furthermore, the amino acid sequence of CD3ζ may be positions 255-366 of SEQ ID No. 1.

[0018] Furthermore, the chimeric antigen receptor may be any of the following:

[0019] B1) The amino acid sequence is the protein shown in positions 22-366 of SEQ ID No. 1;

[0020] B2) is a fusion protein with the same function as B1) obtained by attaching a tag or signal peptide to the N-terminus and / or C-terminus of B1).

[0021] Furthermore, the amino acid sequence of the signal peptide described in B2) may be positions 1-21 of SEQ ID No. 1.

[0022] The chimeric antigen receptor described herein may, from the N-terminus to the C-terminus, sequentially comprise the signal peptide, the single-domain antibody, the CD8a hinge region, the CD8a transmembrane region, the co-stimulatory domain 4-1BB, and the activation domain CD3ζ.

[0023] The tags mentioned in this article include, but are not limited to: GST (glutathione thiotransferase) tag protein, His tag protein (His-tag), MBP (maltose-binding protein) tag protein, Flag tag protein, SUMO tag protein, HA tag protein, Myc tag protein, GFP (green fluorescent protein), CFP (cyan fluorescent protein), YFP (yellow-green fluorescent protein), mCherry (monomer red fluorescent protein), or AviTag tag protein.

[0024] Those skilled in the art can readily mutate the nucleotide sequence encoding the chimeric antigen receptor of the present invention using known methods, such as directed evolution or point mutation. Artificially modified nucleotides having 75% or higher identity with the nucleotide sequence of the chimeric antigen receptor of the present invention, provided they encode the chimeric antigen receptor and have the equivalent function of the chimeric antigen receptor, are derived from and equivalent to the nucleotide sequence of the present invention.

[0025] In this article, identity refers to the similarity of amino acid or nucleotide sequences. The identity of amino acid sequences can be determined using homology search sites on the internet, such as the BLAST page on the NCBI homepage. For example, in Advanced BLAST 2.1, using blastp as the procedure, setting the Expect value to 10, setting all filters to OFF, using BLOSUM62 as the matrix, setting the Gap existence cost, Per residue gap cost, and Lambda ratio to 11, 1, and 0.85 (default values) respectively, and performing a search to calculate the identity of amino acid sequences, then the identity value (%) can be obtained.

[0026] In this document, the at least 80% identity may be at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity.

[0027] The present invention also provides a biomaterial, which may be any of the following:

[0028] C1) encodes the nucleic acid molecule of the single-domain antibody;

[0029] C2) Encodes a nucleic acid molecule that encodes any of the chimeric antigen receptors described herein;

[0030] C3) An expression cassette containing the nucleic acid molecule described in C1) or C2);

[0031] C4) A recombinant vector containing the nucleic acid molecule described in C1) or C2), or a recombinant vector containing the expression cassette described in C3);

[0032] C5) Recombinant microorganisms containing the nucleic acid molecules described in C1) or C2), or recombinant microorganisms containing the expression cassette described in C3), or recombinant microorganisms containing the recombinant vector described in C4);

[0033] C6) Recombinant cells containing the nucleic acid molecules described in C1) or C2), or recombinant cells containing the expression cassette described in C3), or recombinant cells containing the recombinant vector described in C4).

[0034] Among them, the expression cassette described in C3), the recombinant vector described in C4), the recombinant microorganism described in C5), and the recombinant cell described in C6 can all express the chimeric antigen receptor described herein.

[0035] In the above-mentioned biological materials, the nucleic acid molecule described in C1) can be any of the following:

[0036] E1) The nucleotide sequence or coding sequence is the DNA molecule shown in positions 64-414 of SEQ ID No. 2;

[0037] DNA molecules that have 75% or more identity with the nucleotide sequences defined by E2 and E1, and have the same function.

[0038] In the above-mentioned biological materials, the nucleic acid molecule described in C2) can be any of the following:

[0039] F1) The nucleotide sequence or coding sequence is positions 64-1098 of SEQ ID No. 2 or the DNA molecule shown in SEQ ID No. 2;

[0040] DNA molecules that have 75% or more identity of the nucleotide sequence defined by F2 and F1 and have the same function.

[0041] The DNA molecule shown in positions 64-414 of SEQ ID No.2 encodes an amino acid sequence that is a single-domain antibody corresponding to positions 22-138 of SEQ ID No.1.

[0042] The DNA molecule shown in SEQ ID No. 2 encodes the amino acid sequence of the chimeric antigen receptor BCMA-VHH-97CAR shown in SEQ ID No. 1.

[0043] The present invention also provides modified immune effector cells that express any of the chimeric antigen receptors described herein.

[0044] Furthermore, the modified immune effector cells may contain nucleic acid molecules encoding any of the chimeric antigen receptors described herein.

[0045] Furthermore, the immune effector cells may include T cells, NK cells, NKT cells, γδT cells, macrophages, peripheral blood mononuclear cells, and pluripotent stem cells.

[0046] Furthermore, the immune effector cells may include autologous or non-autologous immune effector cells.

[0047] Furthermore, the modified immune effector cells may include CAR-T cells, CAR-NK cells, CAR-NKT cells, CAR-γδT cells, CAR-macrophages (CAR-M cells), CAR-iPSC cells, and CAR-PSC cells.

[0048] Specifically, the present invention also provides CAR-T cells that express any of the chimeric antigen receptors described herein.

[0049] Furthermore, the CAR-T cells may be any of the chimeric antigen receptor-modified T lymphocytes (T cells) described herein, which target BCMA (B-cell maturation antigen, CD269, TNFRSF17).

[0050] In one or more embodiments of the present invention, the CAR-T cells contain and / or express the chimeric antigen receptor gene at positions 64-1098 of SEQ ID No. 2 or as shown in SEQ ID No. 2.

[0051] The CAR-T cells described in this article may possess at least one of the following characteristics:

[0052] G1) secretes the T cell-specific effector molecule IFN-γ;

[0053] G2) specifically kills BCMA-positive tumor cells;

[0054] G3 inhibits the proliferation of BCMA-positive tumor cells.

[0055] This invention also provides the application of the single-domain antibody, any of the chimeric antigen receptors described herein, the biomaterial, or the modified immune effector cells (such as CAR-T cells) in the preparation of products having any of the following functions:

[0056] D1) Prevention or treatment of tumors (such as BCMA-positive tumors);

[0057] D2) Prevention or treatment of BCMA target-related diseases;

[0058] D3) Kills BCMA-positive tumor cells;

[0059] D4) Inhibits the proliferation of BCMA-positive tumor cells;

[0060] D5) Detection of cancer cells expressing BCMA.

[0061] In this article, the BCMA-positive tumors or BCMA target-related diseases may include, but are not limited to, multiple myeloma (MM), chronic lymphocytic leukemia (CML), acute B-cell lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma.

[0062] The present invention also provides a method for preparing modified immune effector cells (such as CAR-T cells), the method comprising: transferring the encoding gene of any of the chimeric antigen receptors described herein into immune effector cells (such as T cells) for expression, thereby obtaining the modified immune effector cells (such as CAR-T cells).

[0063] Furthermore, the method may include the following steps:

[0064] (1) The BCMA-VHH-97CAR gene (SEQ ID No.2) was constructed into a retroviral vector (such as MP71) to obtain a recombinant retroviral vector;

[0065] (2) The recombinant retroviral vector is introduced into packaging cells for packaging to obtain recombinant retrovirus;

[0066] (3) Infect immune effector cells (such as human T cells) with the recombinant retrovirus to obtain recombinant cells.

[0067] Furthermore, the packaging cells may be Phoenix Ecotropic (ECO) cells and PG13 cells.

[0068] Other variants of the single-domain antibody sequences described herein that have improved affinity and / or titer can be obtained using methods known in the art and are included within the scope of this invention. For example, amino acid substitutions can be used to obtain antibodies with further improved affinity. Alternatively, codon optimization of nucleotide sequences can also be used to improve translation efficiency in expression systems used to generate antibodies. Furthermore, polynucleotides comprising sequences whose antibody specificity is optimized by applying directed evolution to any nucleic acid sequence of this invention are also within the scope of this invention.

[0069] In some embodiments, substitutions, insertions, or deletions may occur within one or more complementarity-determining regions or frame regions of the single-domain antibody described in this invention, provided that such changes do not materially reduce the antibody's ability to bind to the antigen. For example, conserved changes (e.g., conserved substitutions, as is well known to those skilled in the art, where conserved substitution of amino acids does not alter the properties and function of the protein) may be made to the complementarity-determining region and / or frame region without materially reducing binding affinity. For example, such changes may occur outside the antigen-contacting residues in the complementarity-determining region.

[0070] The present invention also provides the use of the single-domain antibody, any of the chimeric antigen receptors described herein, or the biomaterials in the preparation of modified immune effector cells.

[0071] In the above applications, the immune effector cells may include T cells, NK cells, NKT cells, γδT cells, macrophages, peripheral blood mononuclear cells, and pluripotent stem cells.

[0072] The present invention also provides pharmaceutical compositions that may contain the single-domain antibody, any of the chimeric antigen receptors described herein, or the modified immune effector cells.

[0073] The pharmaceutical composition can be used to prevent or treat BCMA target-related diseases.

[0074] Furthermore, the pharmaceutical composition may also include one or more pharmaceutically acceptable carriers.

[0075] Furthermore, the pharmaceutically acceptable carrier may be an excipient, stabilizer, suspending agent, or diluent, as is well known to those skilled in the art.

[0076] The present invention also provides a kit that may contain the single-domain antibody, any of the chimeric antigen receptors described herein, or the modified immune effector cells.

[0077] The kit can be used to detect cancer cells expressing BCMA, or to detect the presence of BCMA-positive cancer in a subject.

[0078] The present invention also provides a method for preventing or treating BCMA target-related diseases, the method comprising administering the modified immune effector cells or the pharmaceutical composition to a subject suffering from BCMA target-related diseases.

[0079] In the above method, the BCMA target-related disease can be BCMA-positive cancer.

[0080] The BCMA-positive cancers described in this article may include multiple myeloma, chronic myeloid leukemia, B-cell acute lymphoblastic leukemia, non-Hodgkin lymphoma, and Hodgkin lymphoma.

[0081] The products described herein may include reagents, kits, drugs, or drug compositions.

[0082] This invention designs a novel CAR-T cell targeting BCMA (BCMA-VHH CAR-T cell). Experiments have demonstrated that the BCMA-VHH CAR-T cells of this invention can effectively secrete the T cell-specific effector molecule IFN-γ, thereby effectively and specifically killing BCMA. +The target cells exhibit excellent in vivo tumor-killing activity, significantly inhibiting tumor cell proliferation in mice and significantly prolonging their survival time. The BCMA-VHH CAR-T cells of this invention demonstrate good anti-tumor activity and can be used for immunotherapy of BCMA-targeted diseases (such as multiple myeloma, chronic myeloid leukemia, B-cell acute lymphoblastic leukemia, non-Hodgkin lymphoma, and Hodgkin lymphoma), showing broad clinical application prospects. Attached Figure Description

[0083] Figure 1 This is a schematic diagram of the BCMA-VHH CAR molecular structure.

[0084] Figure 2 The results are the affinity assay results of the BCMA-VHH antibody in Example 2.

[0085] Figure 3 This study describes the detection of CAR expression in BCMA-VHH-97CAR-T cells in Example 4.

[0086] Figure 4 This study aims to detect the cellular function of BCMA-VHH-97CAR-T cells secreting IFN-γ in Example 5.

[0087] Figure 5 This is a cytotoxicity test (CD107a test) of BCMA-VHH-97CAR-T cells in Example 6.

[0088] Figure 6 This study aims to detect the in vitro tumor-killing activity of BCMA-VHH-97CAR-T cells in Example 7.

[0089] Figure 7 This study aims to detect the in vivo tumor-killing activity of BCMA-VHH-97CAR-T cells in Example 8. Detailed Implementation

[0090] The present invention will now be described in further detail with reference to specific embodiments. The given embodiments are merely illustrative of the invention and not intended to limit its scope. The embodiments provided below can serve as a guide for further improvements by those skilled in the art and do not constitute a limitation on the invention in any way.

[0091] Unless otherwise specified, the experimental methods used in the following examples are conventional methods, performed according to the techniques or conditions described in the literature in this field or according to the product instructions. Unless otherwise specified, the materials and reagents used in the following examples are commercially available.

[0092] The retroviral vector MP71 in the following examples is described in the following literature: Engels B, Cam H, et al. Retroviral Vectors for High-Level Transgene Expression in T Lymphocytes[J]. Human Gene Therapy, 2003, 14(12): 1155-1168. The biological material is available to the public from the applicant and is used only for repeating the experiments of the present invention and shall not be used for other purposes.

[0093] The peripheral blood mononuclear cells (PBMCs) in the following examples were derived from venous blood of healthy volunteers.

[0094] The MM1.S cells (BCMA-positive cells) used in the following examples are products of Beijing Bio-Bio Biotechnology Co., Ltd., catalog number bio-129535.

[0095] The hBCMA-his antigen used in the following examples is a product of Shanghai Baiying Biotechnology Co., Ltd., catalog number BCA-H522Y.

[0096] The vector pcDNA3.1 used in the following examples is a product of Changsha Aibiwei Biotechnology Co., Ltd., catalog number: HG-VPI0001.

[0097] In the following examples, the method for preparing BCMA-positive cells K562-BCMA is as follows: BCMA is inserted between the BamHI and EcoRI sites of pcDNA3.1, and the prepared recombinant vector is transfected into K562 cells to obtain BCMA-positive cells K562-BCMA.

[0098] Example 1: Structure and sequence of chimeric antigen receptor

[0099] The chimeric antigen receptor (CAR) designed and constructed in this embodiment is named BCMA-VHH CAR. From the N-terminus to the C-terminus, it consists of a signal peptide, a single-domain antibody (BCMA-VHH), a CD8a hinge region, a CD8a transmembrane region, a co-stimulatory domain 4-1BB, and an activation domain CD3ζ. The structural diagram is shown below. Figure 1 As shown.

[0100] The single-domain antibody (BCMA-VHH) specifically binds to the BCMA protein. This single-domain antibody is the extracellular antigen-binding domain of the CAR, responsible for recognizing and binding to the tumor surface antigen BCMA. A signal peptide is located at the N-terminus of the antigen-binding domain, guiding the peptide chain of the antigen-binding domain to translocate extracellularly, thereby recognizing the tumor cell surface antigen BCMA. The CD8a hinge region is a peptide chain located extracellularly within the CAR, connecting the extracellular antigen-binding domain and the CD8a transmembrane region. The CD8a transmembrane region anchors the single-domain antibody (BCMA-VHH) to the cell membrane. The intracellular signaling domain includes the co-stimulatory domain 4-1BB and the activation domain CD3ζ, which synergistically stimulate T cells, activate intracellular signals, enable T cells to proliferate continuously and release cytokines, enhance the anti-tumor ability of T cells, and simultaneously exert T cell signal transduction functions, promoting a stronger and more durable T cell response.

[0101] The BCMA-VHH CAR designed above can specifically be BCMA-VHH-97CAR.

[0102] The amino acid sequence of BCMA-VHH-97CAR is shown in SEQ ID No. 1. Positions 1-21 of SEQ ID No. 1 are the amino acid sequence of the signal peptide; positions 22-138 of SEQ ID No. 1 are the amino acid sequence of the single-domain antibody (BCMA-VHH-97); positions 139-207 of SEQ ID No. 1 are the amino acid sequences of the CD8a hinge region and transmembrane region (TM); positions 208-254 of SEQ ID No. 1 are the amino acid sequences of the co-stimulatory domains 4-1BB; and positions 255-366 of SEQ ID No. 1 are the amino acid sequences of the activation domain CD3ζ. In the single-domain antibody (BCMA-VHH-97), positions 47-54 of SEQ ID No. 1 are complementarity-determining regions (CDR1); positions 72-78 of SEQ ID No. 1 are complementarity-determining regions (CDR2); and positions 117-127 of SEQ ID No. 1 are complementarity-determining regions (CDR3).

[0103] The nucleotide sequence of BCMA-VHH-97CAR is shown in SEQ ID No. 2. Positions 1-63 of SEQ ID No. 2 are the nucleotide sequence of the signal peptide; positions 64-414 of SEQ ID No. 2 are the nucleotide sequence of the single-domain antibody (BCMA-VHH-97); positions 415-621 of SEQ ID No. 2 are the nucleotide sequences of the CD8a hinge region and the CD8a(TM) transmembrane region; positions 622-762 of SEQ ID No. 2 are the nucleotide sequences of the co-stimulatory domains 4-1BB; and positions 763-1098 of SEQ ID No. 2 are the nucleotide sequences of the activation domain CD3ζ.

[0104] Example 2: BCMA-VHH Antibody Affinity Assay

[0105] 1. ELISA method for detecting antibody clones

[0106] The single-domain antibody BCMA-VHH-97 in Example 1 was obtained by immunizing alpacas with recombinant BCMA protein and then screening using phage display technology. After three rounds of phage screening, BCMA-VHH antibodies with high absorbance values ​​were identified by ELISA. The specific steps are as follows:

[0107] 1) Dilute the target molecule hBCMA-his antigen with carbonate buffer at pH 9.6 to a final concentration of 2 μg / mL, add 100 μL / well to each well, and coat overnight at 4°C;

[0108] 2) Discard the coating solution, wash 3 times with PBST, add 300 μL of 5% skim milk to each well, and block at 37°C for 1 h; 3) Wash once with PBST, add 50 μL of phage culture supernatant and 50 μL of 5% skim milk to each well, and incubate at 37°C for 1 h.

[0109] 4) Wash 5 times with PBST, add 100 μL of horseradish peroxidase-labeled anti-M13 antibody (diluted with PBS at 1:10000) to each well, and incubate at 37°C for 1 h.

[0110] 5) Wash the plate 6 times with PBST. Add TMB colorimetric solution (100 μL / well) for color development, incubate at 37°C for 7 min, then add stop solution (50 μL / well) to terminate the reaction. Measure the optical density at 450 nm.

[0111] Test results as follows Figure 2 As shown, the ELISA value of the BCMA-VHH-97 antibody was higher than 2, and the ratio of the experimental group to the negative control group was 44.3, indicating that the antibody has a high affinity.

[0112] 2. Flow cytometry detection of antibodies

[0113] 2-1. Antibody Preparation

[0114] BCMA-VHH-97 antibody was prepared using genetic engineering methods. The specific steps are as follows:

[0115] 1) To facilitate purification, a human IgG1Fc gene (hFc gene, nucleotide sequence of SEQ ID No. 3, encoding amino acid sequence of SEQ ID No. 4) was added to the 3' end of the encoding gene of the BCMA-VHH antibody (nucleotide sequence of the encoding gene of BCMA-VHH-97 is positions 64-414 of SEQ ID No. 2) to obtain the BCMA-VHH-hFc fusion gene. Then, a BamHI restriction site was added before the 5' start codon and an EcoRI restriction site was added after the 3' stop codon of the fusion gene. The gene was cloned into the eukaryotic expression vector pcDNA 3.1 between the BamHI and EcoRI recognition sites to obtain a recombinant eukaryotic expression vector expressing the C-terminal fusion hFc gene-97-hFc single-domain antibody.

[0116] 2) The eukaryotic expression vector obtained in step 1) was transfected into HEK293 cells using conventional electroporation for expression.

[0117] 3) Protein A has the activity of binding to the Fc fragment of IgG, so Protein A column was used to purify the anti-BCMA single-domain antibody expressed in HEK293 cells (routine purification steps).

[0118] Finally, a purified anti-BCMA single-domain antibody BCMA-VHH-97-hFc fused with the hFc gene was prepared.

[0119] 2-2. Antibody Affinity Detection

[0120] The affinity of the BCMA-VHH antibody was detected by flow cytometry, and the specific steps are as follows:

[0121] 1) Label the antibody BCMA-VHH-97-hFc to be tested with Pierce™ NHS-Fluorescein Antibody Labeling Kit to obtain FITC direct-labeled antibody FITC-BCMA-VHH-97-hFc, which is used for flow cytometry detection;

[0122] 2) Resuspend BCMA-positive K562-BCMA cells to a density of 2×10⁻⁶. 6 Cells / mL, take 100μL and place it in a 96-well V plate, centrifuge, discard the supernatant and collect the cells (K562 as BCMA negative cell control);

[0123] 3) Mix 40 μL of FITC-BCMA-VHH-97-hFc diluted in different serial numbers with the above cells and incubate at room temperature in the dark for 10 min;

[0124] 4) Wash twice by centrifugation with 200 μL FACS buffer, resuspend in 200 μL FACS buffer and immediately perform flow cytometry to detect the mean fluorescence intensity (MFI);

[0125] 5) The strength of affinity is determined by calculating the equilibrium dissociation constant (KD) of the BCMA VHH antibody binding to the target cell using the formula. The smaller the KD value, the stronger the affinity.

[0126] 1 / (MFI-Con)=1 / Fmax+(KD / Fmax)(1 / [BCMA IgG Fc]).

[0127] MFI-Con represents the relative average fluorescence intensity, which is the average fluorescence intensity of the experimental group minus the average background fluorescence intensity; BCMA IgG Fc represents the amount of antibody used (unit: nM).

[0128] A standard curve was plotted with the reciprocal of the antibody usage amount on the x-axis and the reciprocal of the relative average fluorescence intensity on the y-axis, yielding a linear regression equation. Based on the linear regression equation, the intersection of the standard curve and the y-axis is calculated to be 1 / Fmax, and KD is the slope of the straight line multiplied by Fmax. The calculated equilibrium dissociation constants are shown in Table 1.

[0129] Table 1. Equilibrium dissociation constants (KD) of BCMA-VHH-97 and K562-BCMA cells

[0130] BCMA VHH Cloning Affinity constant Kd(nM) #97 5

[0131] Example 3: Preparation of BCMA-VHH CAR-T cells

[0132] The chimeric antigen receptor T cells specifically targeting BCMA (BCMA-VHH CAR-T cells) prepared in this embodiment were obtained by transfecting the BCMA-VHH-97CAR gene (SEQ ID No. 2) into T cells for stable expression. The resulting BCMA-VHH CAR-T cells were named BCMA-VHH-97CAR-T cells. The specific steps are as follows:

[0133] 1. Construction of recombinant retroviral vectors

[0134] (1) The recombinant vector pUC57-BCMA-VHH-97CAR was digested with NotI (NEB) and EcoRI (NEB), and the target gene fragment was recovered by gel digestion. The recombinant vector pUC57-BCMA-VHH-97CAR is a recombinant vector obtained by cloning the BCMA-VHH-97CAR gene (SEQ ID No. 2) into the pUC57 vector, which was synthesized and provided by Qingke Biotechnology Co., Ltd.

[0135] (2) The retroviral vector MP71 was digested with NotI and EcoRI, and the large fragment of the vector was recovered by gel digestion.

[0136] (3) The above target gene fragment and the vector fragment are ligated using T4 ligase (NEB) to obtain the recombinant retroviral vector MP71-BCMA-VHH-97CAR carrying the BCMA-VHH-97CAR gene.

[0137] (4) The recombinant retroviral vector MP71-BCMA-VHH-97CAR was transformed into competent Escherichia coli DH5α. The plasmid was extracted and purified using a plasmid purification kit from Qiagen to obtain the MP71-BCMA-VHH-97CAR plasmid.

[0138] The recombinant retroviral vector MP71-BCMA-VHH-97CAR (i.e., MP71-BCMA-VHH-97CAR plasmid) is obtained by replacing the fragment (small fragment) between the NotI and EcoRI recognition sites of the retroviral vector MP71 with the DNA fragment whose nucleotide sequence is SEQ ID No. 2 in the sequence listing, while keeping the other nucleotide sequences of the retroviral vector MP71 unchanged.

[0139] 2. Retroviral packaging

[0140] The MP71-BCMA-VHH-97CAR plasmid prepared in step 1 was introduced into packaging cells for packaging, completing viral assembly and yielding retroviruses. The specific steps for viral packaging are as follows:

[0141] a) Day 1: Phoenix Ecotropic (ECO) cells should be less than 20 passages and not overly confluent. Use 0.5 × 10⁻⁶ cells. 6 Seed cells at a density of / ml, add 10mL of DMEM medium (10% Fetal Bovine Serum, 2mM L-glutamine, 1% Penicillin / Streptomycin) to a 10cm cell culture dish, mix thoroughly, and incubate overnight at 37°C;

[0142] b) Day 2: Transfect ECO cells when they reach approximately 90% confluency (usually after 14-18 hours of plating). Add chloroquine half an hour before transfection. Prepare 15 μg of plasmid, 250 μL of 1.5M CaCl2, and 1 ml of H2O to a total volume of 1.25 mL. Add an equal volume of 2×HBS to the plasmid complex, mix well, and incubate at room temperature for 15 minutes. Then, add the mixture to ECO cell culture dishes. Incubate at 37°C for 6 hours, remove the culture medium, wash once with PBS, and add 10 ml of preheated fresh culture medium.

[0143] c) Day 4: Collect the supernatant 48 hours after transfection, filter it through a 0.45 μm filter to obtain the retrovirus solution, aliquot and store at -80℃;

[0144] d) Add 1.2 mL of 15 μg / mL Retronectin coating solution to each well of an NTC 6-well plate and incubate overnight at 4°C;

[0145] e) Carefully aspirate the blocking solution, add 2 mL / well of PBS to wash, add 5 mL of the above virus solution to each well, centrifuge at 32℃ and 2000×g for 2 h, and discard the unbound virus supernatant;

[0146] f) Take PG13 cells in the logarithmic growth phase, wash them once with 10 mL of PBS, add 1 mL of 0.25% recombinant trypsin, and let them stand at room temperature for 2-3 min;

[0147] g) Add 5 ml of complete culture medium containing 10% FBS to stop digestion, and centrifuge at 1500 rpm for 5 min;

[0148] h) Discard the supernatant and adjust the cell density to 0.5 × 10⁻⁶ cells using complete culture medium. 5 Add 3 mL of the above-mentioned virus-coated NTC 6-well plate to each well, bringing the final cell count to 1.5 × 10⁻⁶ cells / mL. 5 cell / hole;

[0149] i) Incubate at 37℃ and 5% CO2 for 48 hours;

[0150] j) After subculturing for 1-2 generations, transfer to T175 culture flasks and culture in DEME medium containing 12% FBS for 2 days;

[0151] k) Replace with new DEME medium containing 12% FBS and continue culturing for 48 hours. Collect the supernatant, filter it through a 0.45 μm filter to obtain the retrovirus solution, aliquot and store at -80℃.

[0152] 3. Retrovirus infection of human T cells

[0153] a) Resuscitate frozen peripheral blood mononuclear cells (PBMCs) from healthy individuals and adjust the cell density to 1 × 10⁶ cells / cm² using RPMI-1640 medium containing 10% fetal bovine serum (FBS). 6 -2×10 6 Cells / mL.

[0154] b) PBMCs were collected using Ficoll separation solution (Tianjin Haoyang), and CD3 was obtained by magnetic bead separation (Miltenyi). + T cells, according to magnetic beads: CD3 + T cells were activated by adding clinical-grade Dynabeads Human T Expander CD3 / CD28 magnetic beads (Invitrogen) at a ratio of 3:1, and the T cells were cultured in 24-well cell culture plates.

[0155] c) Dilute RetroNectin (TAKARA) to a final concentration of 15 μg / mL with PBS and coat non-tissue culture plates with 1.2 mL per well in a 6-well plate. Incubate overnight at 4°C, protected from light, for later use.

[0156] d) Two days after T cell activation culture, remove the coated 6-well plate, discard the coating solution, and wash the plate once with PBS.

[0157] e) Add 5-6 mL of the retrovirus solution prepared in step 2 to each well, centrifuge at 32°C and 2000×g for 2 h, and discard the supernatant. Add 3 mL of activated T cell suspension containing hIL-2 (500 U / mL) to each well and continue culturing for 1 day.

[0158] f) After cell infection, monitor cell density daily and supplement T cell culture medium containing 500 U / mL IL-2 as needed to maintain T cell density at 5 × 10⁻⁶ cells / mL. 5 The volume is around 100 mL, which facilitates cell proliferation.

[0159] g) This yields CAR-T cells infected with the retrovirus prepared in step 2, named BCMA-VHH-97CAR-T cells (i.e. T cells expressing the BCMA-VHH-97CAR gene with the nucleotide sequence SEQ ID No. 2).

[0160] The constructed BCMA-VHH-97CAR-T cells and CTR T cells (i.e., T cells without virus transfection, serving as a negative control) were cultured in RPMI-1640 containing 10% fetal bovine serum (FBS) at 37°C and marked as day D0. Various functional tests were performed on day D10.

[0161] Example 4: Detection of CAR expression in BCMA-VHH CAR-T cells

[0162] The constructed BCMA-VHH-97CAR-T cells contain the BCMA-VHH-97CAR gene with the nucleotide sequence of SEQ ID No. 2, and express the chimeric antigen receptor BCMA-VHH-97CAR with the amino acid sequence of SEQ ID No. 1. The CAR expression detection steps are as follows:

[0163] 1. After centrifuging the cells (1500 rpm × 5 min), discard the supernatant. Add 200 μL of FACSbuffer (1 × PBS containing 0.1% NaN3 and 2% FBS) to each well of a 96-well circular plate and resuspend. Centrifuge at 1500 rpm for 5 min.

[0164] 2. Add 60 μL of the prepared fluorescently labeled anti-human CD8-PerCP-Cy5.5 / BCMA-GFP to each well, resuspend and mix well, and incubate at 4℃ for 30 min;

[0165] 3. Add 200 μL of FACS buffer to each well and centrifuge at 1500 rpm for 5 min;

[0166] 4. Discard the supernatant, resuspend the cells in 400 μL of FACS buffer, transfer them to a flow cytometry reading tube, and read the cells using a flow cytometer (BDCanto-II) to analyze the percentage of BCMA antibody in BCMA-VHH-97CAR-T cells.

[0167] Test results as follows Figure 3 As shown, BCMA-VHH-97CAR-T cells can express BCMA antibodies well, indicating that the expression of CAR molecules in BCMA-VHH-97CAR-T cells has reached the expected design.

[0168] Example 5: Functional detection of the secretion effector molecule IFN-γ

[0169] 1. The test cells, BCMA-VHH-97 CAR-T cells and CTR T cells (i.e., T cells without virus transfection, serving as a negative control), were adjusted to a cell density of 2 × 10⁻⁶. 6 Add 100 μL of the sample to a 96-well U-plate and add MM1.S cells at a ratio of 1:1 (test cells: target cells). Add Brefeldin A (Med Chem Express, HY-16592) to each well to a final concentration of 5 μg / mL. Incubate at 37°C for 6 hours.

[0170] CTR+MM1.S: 1 mL per well, total 1×10⁻⁶ 6 Add 1 mL of the solution to 10 virus-free T cells (CTR T cells) for a total of 1 × 10⁻⁶ cells. 6 MM1.S cells;

[0171] BCMA-VHH-97CAR-T cells + MM1.S: 1 mL per well, total 1 × 10⁻⁶ 6 1 mL of 1 × 10⁸ BCMA-VHH-97CAR-T cells were added. 6 MM1.S cells;

[0172] 2. After incubation, perform flow cytometry staining. The procedure is as follows:

[0173] (1) After centrifuging the cells (1500 rpm × 5 min), discard the supernatant, add 200 μL of FACS buffer (1×PBS containing 0.1% NaN3 and 2% FBS) to each well to resuspend, centrifuge at 1500 rpm for 5 min, and repeat this step twice;

[0174] (2) Add 60 μL of the prepared fluorescently labeled BCMA(rp)-PE to each well, resuspend and mix well, and incubate in the dark at room temperature for 10 min.

[0175] (3) Add 200 μL of FACS buffer to each well, centrifuge at 1500 rpm for 5 min and then discard the supernatant;

[0176] (4) Add 150 μL of Cytofix / Cytoperm (BD Company, catalog number 55472) to each well, resuspend and mix well, and incubate at room temperature in the dark for 15 min;

[0177] (5) After centrifuging at 1500 rpm for 5 min and discarding the supernatant, add 200 μL of Perm / Wash buffer (BD Company, catalog number 554723) to each well, resuspend and mix well, centrifuge at 1500 rpm for 5 min, and wash twice.

[0178] (6) Add 20 μL of diluted APC-labeled anti-human IFN-γ (Biolegend, catalog number 506510) to each well, resuspend and mix well, and incubate in the dark at room temperature for 20 min.

[0179] (7) Add 200 μL of Perm buffer to each well and centrifuge at 1500 rpm for 5 min. After discarding the supernatant, resuspend the cells in 400 μL of FACS buffer and transfer them to flow cytometry reading tubes. Read the cells using a flow cytometer (BD Canto-II) and analyze the percentage of the functional effector molecule IFN-γ in BCMA-VHH-97CAR-T cells and control cells.

[0180] Test results as follows Figure 4As shown, after co-culturing with MM1.S target cells, BCMA-VHH-97CAR-T cells were able to secrete the T cell-specific effector molecule IFN-γ very well.

[0181] Example 6: Detection of CD107a in BCMA-VHH CAR-T cells

[0182] The degranulation molecule CD107a can be used to measure the activation level of CAR-T cells. The specific procedure is as follows:

[0183] 1. The test cells, BCMA-VHH-97 CAR-T cells and CTR T cells (i.e., T cells without virus transfection, serving as a negative control), were adjusted to a cell density of 2 × 10⁻⁶. 6 MM1.S cells were added to 100 μL of the test cells to target cells ratio of 1:1 in a 96-well U-plate. CTR+MM1.S: 1 mL per well, totaling 1 × 10⁶ cells. 6 Add 1 mL of the solution to 10 virus-free T cells (CTR T cells) for a total of 1×10⁻⁶ cells. 6 MM1.S cells; BCMA-VHH-97CAR-T cells + MM1.S: 1 mL per well, total 1 × 10⁶ 6 1 mL of 1 × 10⁸ BCMA-VHH-97CAR-T cells were added. 6 MM1.S cells; add 1 μL of APC anti-human CD107a antibody to each well and incubate for 1 h in an incubator.

[0184] 2. After incubation, perform flow cytometry staining. The procedure is as follows:

[0185] (1) After centrifuging the cells (1500 rpm × 5 min), discard the supernatant, add 200 μL of FACS buffer (1×PBS containing 0.1% NaN3 and 2% FBS) to each well to resuspend, centrifuge at 1500 rpm for 5 min, and repeat this step twice;

[0186] (2) Add 60 μL of the prepared fluorescently labeled CD8 percp-cy5.5 to each well, resuspend and mix well, and incubate in the dark at room temperature for 10 min;

[0187] (3) Add 200 μL of FACS buffer to each well, centrifuge at 1500 rpm for 5 min and then discard the supernatant;

[0188] (4) Resuspend the cells in 400 μL of FACS buffer and transfer them to flow cytometers. Read the cells using a flow cytometer (BDCanto-II) and analyze the percentage of the functional effector molecule CD107a in BCMA-VHH-97CAR-T cells and control cells.

[0189] Test results as follows Figure 5 As shown, after co-culturing with MM1.S target cells, BCMA-VHH-97CAR-T cells were able to express CD107a molecules well, with the expression of secreted CD107a molecules exceeding 40%, indicating that BCMA-VHH-97CAR-T cells have a high level of activation and good killing activity against tumor cells.

[0190] Example 7: Detection of cytotoxic effects of BCMA-VHH CAR-T cells

[0191] 1. Adjust the cell density of effector cells BCMA-VHH-97 CAR-T cells and CTR T cells to 2×10⁻⁶. 6 Cells / mL; MM1.S target cells were added at different effector-to-target ratios (9:1, 3:1, 1:1, 0.3:1) (the cell density of the target cells under the 1:1 condition was 2 × 10⁻⁶ cells / mL). 4 (1 cell), the cells were mixed in a 96-well V plate and cultured at 37°C for 4 hours.

[0192] 2. Measure the LDH release level of tumor cells according to the LDH detection kit instructions (Promega, G1780).

[0193] 3. Measure the fluorescence values ​​using a TECAN Spark microplate reader, and calculate the cytotoxicity of BCMA-VHH-97 CAR-T cells by taking the average value of the three replicate wells:

[0194] %Cytotoxicity=100×(Experimental–Effector Spontaneous–Target Spontaneous) / (Target Maximum–Target Spontaneous)

[0195] Test results as follows Figure 6 As shown, BCMA-VHH-97CAR-T cells can effectively and specifically kill BCMA. + Target cells (MM1.S cells), while control CTR T cells were subjected to BCMA. + It has no killing effect on target cells.

[0196] Example 8: In vivo tumor-killing activity assay of BCMA-VHH CAR-T cells

[0197] 1. Female NSG mice (Shanghai Southern Model Biotechnology Co., Ltd., catalog number NM-NSG-001, 8-10 weeks old) were injected intravenously with 2.0 × 10⁻⁶ mg / L of the drug.6 MM1.S-Luc-GFP cells;

[0198] 2. Seven days after vaccination, the animals were randomly divided into 6 groups, with each animal receiving a tail vein injection of 4.0 × 10⁻⁶ mg / L. 6 One BCMA-VHH-97CAR-T cell or CTR T (i.e., virus-free T cells, as a control) cell, and marked as day D0;

[0199] 3. On days 7, 14, 21, 28, 35, and 42, animals were injected intraperitoneally with 20 mL / kg of D-fluorescein potassium. 10–15 min after injection, the tumor signal intensity was measured using a small animal in vivo imaging system under isoflurane anesthesia for 60 s.

[0200] Test results as follows Figure 7 As shown, compared to the CTR control group, BCMA-VHH-97CAR-T cells not only significantly inhibited the proliferation of tumor cells in mice, but also significantly prolonged the survival time of mice. Figure 7 (A, B). Survival curves of tumor-bearing mice in each group during the experiment are shown in Figure 1. Figure 7 In the CTR group, animals died successively by day 28 due to tumor burden; based on tumor signal size, mortality was correlated with tumor burden. In the #97 group, one mouse survived by day 35. These results suggest that administration of #97 (BCMA-VHH-97 CAR-T cells) significantly inhibits tumor cells and prolongs mouse survival.

[0201] The present invention has been described in detail above. Those skilled in the art will recognize that the invention can be practiced in a wide range of ways with equivalent parameters, concentrations, and conditions without departing from its spirit and scope, and without requiring unnecessary experiments. While specific embodiments have been provided, it should be understood that further modifications can be made to the invention. In summary, according to the principles of the invention, this application is intended to include any changes, uses, or improvements to the invention, including changes made using conventional techniques known in the art that depart from the scope disclosed herein.

Claims

1. A single-domain antibody that specifically targets BCMA, characterized in that, The single-domain antibody contains complementarity-determining regions CDR1 (positions 47-54) of SEQ ID No. 1, CDR2 (positions 72-78) of SEQ ID No. 1, and CDR3 (positions 117-127) of SEQ ID No. 1, respectively.

2. The single-domain antibody according to claim 1, characterized in that, The amino acid sequence of the single-domain antibody is any of the following: A1) Bits 22-138 of SEQ ID No. 1; The amino acid sequences shown in A2) and A1) have at least 80% identity and the same function.

3. A chimeric antigen receptor, characterized in that, The chimeric antigen receptor comprises, from the N-terminus to the C-terminus, a signal peptide, the single-domain antibody as described in claim 1 or 2, a CD8a hinge region, a CD8a transmembrane region, a co-stimulatory domain 4-1BB, and an activation domain CD3ζ.

4. The chimeric antigen receptor according to claim 3, characterized in that, The amino acid sequence of the signal peptide is positions 1-21 of SEQ ID No.

1.

5. The chimeric antigen receptor according to claim 3 or 4, characterized in that, The amino acid sequence of the chimeric antigen receptor is shown in SEQ ID No.

1.

6. A biomaterial, characterized in that, The biomaterial is any one of the following: C1) A nucleic acid molecule encoding the single-domain antibody of claim 1 or 2; C2) The nucleic acid molecule encoding any of the chimeric antigen receptors described in claims 3-5; C3) An expression cassette containing the nucleic acid molecule described in C1) or C2); C4) A recombinant vector containing the nucleic acid molecule described in C1) or C2), or a recombinant vector containing the expression cassette described in C3); C5) Recombinant microorganisms containing the nucleic acid molecules described in C1) or C2), or recombinant microorganisms containing the expression cassette described in C3), or recombinant microorganisms containing the recombinant vector described in C4); C6) Recombinant cells containing the nucleic acid molecules described in C1) or C2), or recombinant cells containing the expression cassette described in C3), or recombinant cells containing the recombinant vector described in C4).

7. CAR-T cells, characterized in that, The CAR-T cells express the chimeric antigen receptor as described in any one of claims 3-5.

8. The use of the CAR-T cells according to claim 7 in the preparation of products having any of the following functions: D1) Prevention or treatment of multiple myeloma; D2) Kills multiple myeloma cells; D3) Inhibits the proliferation of multiple myeloma cells.

9. The use of the single-domain antibody according to claim 1 or 2 in the preparation of a product for detecting cancer cells expressing BCMA.

10. A method for preparing CAR-T cells, characterized in that, The preparation method includes: transferring the encoding gene of the chimeric antigen receptor as described in any one of claims 3-5 into T cells for expression, thereby obtaining the CAR-T cells.

Citation Information

Patent Citations

  • Anti-BCMA nano antibody as well as preparation method and application thereof

    CN116396385A

  • CLL1-targeting CAR-T cell as well as preparation method and application thereof

    CN116445415A